Silence Therapeutics plc (SLN): Cost of Revenue
$215.0K
Year ended 2025-12-31
$87.0K
Trailing 12 months to 2026-06-30
-74.8%
3-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $215.0K | -98.2% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $11.81M | -8.2% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $12.87M | -4.4% | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | $13.46M | n/a | 2025-02-27, From 2022-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Silence Therapeutics plc (SLN) | 2025-12-31 | $215.0K | -98.2% |
| Quantum Cyber N.V. (QUCY) | 2025-12-31 | $147.3K | -53.8% |
| PMGC Holdings Inc. (ELAB) | 2025-12-31 | $404.8K | n/a |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $164.0K | -92.3% |
| Polomar Health Services, Inc. (PMHS) | 2025-12-31 | $188.1K | +573.8% |
| Lexaria Bioscience Corp. (LEXX) | 2025-08-31 | $2.7K | -43.6% |
| Scienture Holdings, Inc. (SCNX) | 2025-12-31 | $100.1K | -23.4% |
| Hyperion Defi, Inc. (HYPD) | 2025-12-31 | $303.3K | -92.3% |
| Onconetix, Inc. (ONCO) | 2025-12-31 | $182.5K | -87.6% |
Compare SLN, QUCY, ELAB, BTAIQ side by side · Screen every company in Pharmaceutical Preparations ↗